Aetna and Humana Inc. are entered into a definitive agreement where Aetna will acquire all outstanding shares of Humana for a combination of cash and stock valued at $37 billion. The Closing will be approximately $230 per Humana share. The joint release also noted that, “The combined company will be well positioned to offer a broad choice […]
News: Aetna Buying Humana $AET Read More »
Patterson Companies, Inc., announced that it has entered into a definitive agreement with Madison Dearborn Partners to sell its Medical Business. The Buyer is a large Equity firm in Chicago, and the price of the deal is $715 million in cash. According to Scott P. Anderson, chairman and chief executive officer of Patterson Companies, “Patterson’s strategy
News: Patterson Selling Medical Business $PDCO Read More »
U.S. Food and Drug Administration (FDA), has cleared the Magellan™ 10Fr Robotic Catheter for use in the peripheral vasculature. The product is a major brand of M/s Hansen Medical, Inc., whose shares rise to 12.8% after the news. The Magellan 10Fr Robotic Catheter is the latest addition to the family of robotic catheters used with the Magellan
News: FDA Clears Magellan Catheter $HNSN Read More »
Teva Pharmaceutical Industries Ltd. and Xenon Pharmaceuticals Inc., has jointly conducted the placebo-controlled Phase 2b study designed to evaluate the safety and efficacy of topically applied TV-45070 (4% and 8% w/w ointment) in patients with chronic pain due to osteoarthritis (OA) of the knee. The results were not sufficient to make any difference from placebo in
News: Xenon unable to Pass 2b Trials $XENE Read More »
Biocept, Inc., a molecular diagnostics company, has launched liquid Biopsy test for Breast and Lungs Cancer. It will help physicians identify patients who may be receptive to certain breast and lung cancer treatments. “The launch of FGFR1 testing is part of our strategy to use liquid biopsy to transform the field of personalized medicine,” said Raaj Trivedi,
News: Biocept Launched Liquid Biopsy Test $BIOC Read More »
